What this pack is
Motilium is the brand name in this record; domperidone is the generic name. Read both together with the dosage form (exact dosage form to be checked from the current pack).
PACK CHECK · MARKET FIRST
MotiliumGeneric namedomperidone
Mainland China pack-name cue吗丁啉®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
The Irish SmPC describes dopamine-receptor blockade, faster gastric emptying and anti-emetic effects, rather than reduced acid secretion.
Read source: IE ↗reviewed 2026-09-09More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 吗丁啉®
- International brand name
- Motilium
- Source-scoped market brand names
- 吗丁啉® · Mainland ChinaSource-scoped evidence ↗Domperidone tablets; the first-party leaflet lists Chinese approval identifier H10910003.
- Motilium · IrelandCurrent regulator record ↗HPRA authorisation PA23490/022/002 does not establish sale eligibility elsewhere.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- domperidone
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
Mainland China trade-name search cue:吗丁啉®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
CN · Chinese first-party leaflet, revised 13 May 2026
10 mg domperidone per tablet; 30 tablets/carton
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- H10910003
- Form and route
- Domperidone tablets · Oral (product-identity field)
- Listing review
- Cited product evidence reviewed 2026-09-09; actual marketing, stock and availability are not established.
- domperidone
- 10 mgStrength per tablet, not an individual tablet count
- Package
- 30 tablets per carton
CN · Chinese first-party leaflet, revised 13 May 2026
10 mg domperidone per tablet; 42 tablets/carton
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- H10910003
- Form and route
- Domperidone tablets · Oral (product-identity field)
- Listing review
- Cited product evidence reviewed 2026-09-09; actual marketing, stock and availability are not established.
- domperidone
- 10 mgStrength per tablet, not an individual tablet count
- Package
- 42 tablets per carton
IE · Ireland HPRA, 26 Jan 2026
10 mg domperidone per tablet; 10 tablets/carton
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- PA23490/022/002
- Form and route
- Domperidone film-coated tablets · Oral (product-identity field)
- Listing review
- Cited product evidence reviewed 2026-09-09; actual marketing, stock and availability are not established.
- domperidone
- 10 mgStrength per tablet, not an individual tablet count
- Package
- 10 tablets per carton
IE · Ireland HPRA, 26 Jan 2026
10 mg domperidone per tablet; 20 tablets/carton
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- PA23490/022/002
- Form and route
- Domperidone film-coated tablets · Oral (product-identity field)
- Listing review
- Cited product evidence reviewed 2026-09-09; actual marketing, stock and availability are not established.
- domperidone
- 10 mgStrength per tablet, not an individual tablet count
- Package
- 20 tablets per carton
PACKAGE-VISUAL STATUS
Pack counts verified; exact carton photographs not shown
China lists 30 and 2×21 tablets; Ireland lists 10 or 20, not necessarily all marketed. Retail or other-country images are not substitutes, and appearance cannot authenticate a pack.
LABEL READING · NOT A PRESCRIPTION
Large-print leaflet reading: age, heart history and the medicine list
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The Chinese Motilium leaflet (13 May 2026) is the primary original here. Match the pack, then read contraindications and precautions; OTC does not mean suitable for everyone.
- If over 60, with heart, liver or kidney problems, or taking several medicines, ask a clinician or pharmacist to review the whole list.
- The Chinese leaflet advises consultation if symptoms persist after 3 days and usually limits use to one week; this is not an instruction to start a course.
- The leaflet calls for stopping and prompt consultation if symptoms may indicate arrhythmia. Fainting, severe chest discomfort or breathing difficulty needs emergency help.
- 10 mg per tablet is different from the carton count. Check splitting and administration against the exact leaflet and professional advice, not appearance or coating alone.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkXi’an Janssen · Mainland China · Manufacturer public leaflet · 2026-09-09
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- Mainland China · 1
- Ireland · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeXi’an Janssen: Motilium / domperidone tablets OTC leaflet, revised 13 May 2026; H10910003 ↗reviewed 2026-09-09
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- HPRA · Ireland · Regulatory product record or public product information · 2026-09-09HPRA: Motilium 10mg Film-Coated Tablets, PA23490/022/002; SmPC 26 January 2026 ↗reviewed 2026-09-09
- HPRA · Ireland · Regulatory product record or public product information · 2026-09-09HPRA: Motilium 10mg Film-Coated Tablets, Irish authorisation and pharmacy-supply conditions ↗Current regulatory record · reviewed 2026-09-09
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Motilium (domperidone). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Motilium is the brand in this record and domperidone is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- Xi’an Janssen: Motilium / domperidone tablets OTC leaflet, revised 13 May 2026; H10910003 ↗reviewed 2026-09-09
- HPRA: Motilium 10mg Film-Coated Tablets, PA23490/022/002; SmPC 26 January 2026 ↗reviewed 2026-09-09
- HPRA: Motilium 10mg Film-Coated Tablets, Irish authorisation and pharmacy-supply conditions ↗Current regulatory record · reviewed 2026-09-09
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
Also taking levofloxacin / Cravit / Levaquin?
The Irish Motilium SmPC lists levofloxacin among QT-prolonging medicines contraindicated with domperidone. Have both packs reviewed promptly; do not solve it by self-spacing doses.
Open the Levaquin / levofloxacin record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-09-09CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
Also taking clarithromycin or another anti-infective?
The Irish SmPC contraindicates potent CYP3A4 inhibitors such as clarithromycin. This is not an exhaustive interaction list; bring every medicine for review.
Open the BIAXIN / clarithromycin record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-09-09HOW IT WORKS · NOT A TREATMENT PLAN
It helps gut movement; not all stomach medicines do the same thing
- Gut effects do not rule out cardiac electrical effects. QT is an ECG interval; stomach symptoms do not measure that risk.
- CYP3A4 contributes to its metabolism. Inhibiting it can raise drug exposure; separating doses by an hour or two is not a reliable solution.
- Antacids and acid-suppressing medicines should not be taken simultaneously with it. A pharmacist should check the actual schedule rather than assume all stomach medicines can be combined.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- Xi’an Janssen: Motilium / domperidone tablets OTC leaflet, revised 13 May 2026; H10910003 ↗reviewed 2026-09-09
- HPRA: Motilium 10mg Film-Coated Tablets, PA23490/022/002; SmPC 26 January 2026 ↗reviewed 2026-09-09
- HPRA: Motilium 10mg Film-Coated Tablets, Irish authorisation and pharmacy-supply conditions ↗Current regulatory record · reviewed 2026-09-09
- EMA: domperidone referral and 2014 restrictions on nausea/vomiting use and cardiac risk ↗Historical public record · reviewed 2026-09-09
- FDA: Information about domperidone; not FDA-approved for human use ↗Current regulatory record · reviewed 2026-09-09
SOURCE-TRACEABLE ARCHIVE
Motiliumdomperidone
This page links to public primary-source material for Motilium. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
First authorisation of this Irish licence
This date belongs to PA23490/022/002, not U.S. approval or a global first launch.
HPRA: Motilium 10mg Film-Coated Tablets, Irish authorisation and pharmacy-supply conditions ↗European restrictions endorsed
Regulatory review supported restricted nausea/vomiting use with cardiac-risk precautions.
EMA: domperidone referral and 2014 restrictions on nausea/vomiting use and cardiac risk ↗Chinese public leaflet revised
The current first-party download prints this revision date.
Xi’an Janssen: Motilium / domperidone tablets OTC leaflet, revised 13 May 2026; H10910003 ↗
MARKET SCOPE
Market-record boundary
Mainland China
Public first-party OTC leafletMotilium / domperidone tablets, 10 mg. A separate current NMPA database check is not completed; no stock claim is made.
Ireland
HPRA-authorised record; supply conditions vary by packThe licence permits non-prescription pharmacy supply for the small pack; packs above 10 tablets require a prescription. Listed packs are not live inventory.
United States
Not FDA-approved for human useFDA states it is unapproved. Other countries’ leaflets do not establish U.S. marketing or purchasing eligibility.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Why do the Chinese and Irish indications differ?
Authorised scope differs by market. The Chinese first-party product page includes dyspepsia symptoms; the current Irish label lists nausea and vomiting. Follow the actual local product, not whichever wording is broader.
Can it be used to increase milk supply?
Do not self-use it to increase milk supply. FDA describes unestablished benefit, serious cardiac risks and reports of neuropsychiatric events during withdrawal; if already using it, seek clinical review.
Does half a tablet guarantee a safer dose?
No. Suitability, splittability and the prescribed amount are separate questions. Halving does not remove a contraindication.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.